Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Toricelli, Mariana ^a   Melo, Fabiana H M ^a   Peres, Giovani B ^a   Silva, Débora C P ^b   Jasiulionis, Miriam G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Anoikis; Beta1 integrin; CD63; Malignant transformation; Melanoma; PI3 K pathway; Timp1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTIBODY; BETA1 INTEGRIN; CD63 ANTIGEN; MELAN A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; WORTMANNIN;

ANOIKIS; ARTICLE; CANCER CELL; CARCINOGENESIS; COLONY FORMATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MELANOCYTE; MELANOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANOIKIS; ANTIGENS, CD29; ANTIGENS, CD63; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NEOPLASM METASTASIS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

MURINAE; MUS;

EID: 84875336871     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-22     Document Type: Article

References (58)

1. Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007, 20:80-91. 10.1111/j.1600-0749.2006.00356.x, 17371435.
2. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, et al. Molecular classification of melanoma using real-time quantitative reverse transcriptasepolymerase chain reaction. Cancer 2005, 104:1678-1686. 10.1002/cncr.21372, 16116595.
3. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchoragedependent cells. Biochem Pharmacol 2008, 76:1352-1364. 10.1016/j.bcp.2008.07.023, 18708031.
4. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13:555-562. 10.1016/S0955-0674(00)00251-9, 11544023.
5. Howlett AR, Bailey N, Damsky C, Petersen OW, Bissell MJ, et al. Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci 1995, 108:1945-1957.
6. Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996, 13:1709-1719.
7. Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001, 61:1707-1716.
8. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, et al. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59:2724-2730.
9. Wang LH. Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004, 71:361-367.
10. Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA. Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 2006, 8:231-241. 10.1593/neo.05781, 1578519, 16611417.
11. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44-48. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P, 9988231.
12. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298. 10.1158/1078-0432.CCR-03-0360, 15073104.
13. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995, 1:899-906.
14. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898-906.
15. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934-3942. 10.1038/sj.emboj.7601281, 1560352, 16917503.
16. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 7:405-12.
17. Ricca TI, Liang G, Suenaga AP, Han SW, Jones PA, et al. Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol 2009, 2:329-340. 2781071, 19956395.
18. Bayascas JR. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signaling pathways. Cell Cycle 2008, 19:2978-2982.
19. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987, 39:414-418. 10.1002/ijc.2910390324, 3102392.
20. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011, 23:3853-68.
21. Carvalho RF, Dariolli R, Justulin JL, Sugizaki MM, Politi OM, Cicogna AC, Felisbino S, Dal PSM. Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. Int J Exp Pathol 2006, 6:437-443.
22. Jasiulionis MG, Chammas R, Ventura AM, Travassos LR, Brentani RR. Alpha6beta1-Integrin, a major cell surface carrier of beta1-6-branched oligosaccharides, mediates migration of EJ-ras-transformed fibroblasts on laminin-1 independently of its glycosylation state. Cancer Res 1996, 7:1682-9.
23. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6. 10.1126/scisignal.127re6, 2493614, 18612141.
24. Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, et al. Integrins and signal transduction. Adv Exp Med Biol 2010, 674:43-54. 10.1007/978-1-4419-6066-5_5, 20549939.
25. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009, 315:1584-1592. 10.1016/j.yexcr.2008.09.020, 18930046.
26. Bourboulia D, Stetler-Stevenson W. Matrix Metalloproteinases (MMPs) and Tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010, 3:161-168.
27. Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 2004, 64:952-961. 10.1158/0008-5472.CAN-03-2445, 14871825.
28. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001, 158:1207-1215. 10.1016/S0002-9440(10)64070-9, 1891911, 11290537.
29. Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995, 86:4506-4515.
30. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92:1342-1349.
31. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002, 102:39-44. 10.1006/jsre.2001.6318, 11792150.
32. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011, 17:2417-2425. 10.1158/1078-0432.CCR-10-2402, 3415234, 21487066.
33. Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, Jeon SK, Kim HC, Yoo JS, Ko JH. Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression. J Biol Chem 2012, 287:32467-78. 10.1074/jbc.M112.370064, 22859303.
34. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, et al. Progression related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999, 30:562-567. 10.1016/S0046-8177(99)90202-2, 10333228.
35. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
36. Tsagaraki I, Tsilibary EC, Tzinia AK. TIMP-1 interaction with alphavbeta3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF alphainduced apoptosis. Cell Tissue Res 2010, 342:87-96. 10.1007/s00441-010-1025-1, 20798956.
37. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006, 25:99-113. 10.1007/s10555-006-7893-x, 16680576.
38. Sugiura T, Berditchevski F. Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999, 146:1375-1389. 10.1083/jcb.146.6.1375, 2156113, 10491398.
39. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4:e5219. 10.1371/journal.pone.0005219, 2667632, 19381331.
40. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001, 114:4143-4151.
41. Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, et al. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991, 266:3239-3245.
42. Hemler ME. Specific tetraspanin functions. J Cell Biol 2001, 155:1103-1107. 10.1083/jcb.200108061, 2199333, 11756464.
43. Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME. A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 1997, 272:2595-2598. 10.1074/jbc.272.5.2595, 9006891.
44. Yauch RL, Hemler ME. Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 2000, 351:629-637. 10.1042/0264-6021:3510629, 1221402, 11042117.
45. Yauch RL, Kazarov AR, Desai B, Lee RT, Hemler ME. Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151. J Biol Chem 2000, 275:9230-9238. 10.1074/jbc.275.13.9230, 10734060.
46. Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, et al. Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost 2003, 1:1161-1173. 10.1046/j.1538-7836.2003.00316.x, 12871315.
47. Berditchevski F, Odintsova E. Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol 1999, 146:477-492. 10.1083/jcb.146.2.477, 2156181, 10427099.
48. Jang HI, Lee H. A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 2003, 35:317-323. 10.1038/emm.2003.43, 14508073.
49. Humphries MJ. Integrin structure. Biochem Soc Trans 2000, 28:311-339. 10.1042/0300-5127:0280311, 10961914.
50. Berditchevski F, Odintsova E. Tetraspanins as regulators of protein trafficking. Traffic 2007, 8:89-96. 10.1111/j.1600-0854.2006.00515.x, 17181773.
51. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001, 276:7974-7984. 10.1074/jbc.M008650200, 11113129.
52. Dorahy DJ, Lincz LF, Meldrum CJ, Burns GF. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996, 319:67-72. 1217736, 8870650.
53. McMannus HJ, Alessi DR, Ashby PR, Precott AR, Murray-Tait V, Armit LJ, Arthur JS, Alessi DR. The vivo role PtdIns (3, 4, 5)P3 binding to PDK1 PH domain defined by knokin mutation. EMBO J 2004, 10:2071-82.
54. Bayascas JR, Wullschleger S, Sakamoto K, Garcia-Matinez JM, Clacher C, Komander D, Van Aalten DM, Boini KM, Lang F, Lipina C, Logie L, Sutherland C, Chudek J, Van Diepen J, Voshol PJ, Lucocq JM, Alessi DR. Mutation of the PDK1 domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 2008, 10:3258-72.
55. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 3:307-13.
56. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 9:2050-6.
57. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006, 23:7054-8.
58. Davidsen ML, Würtz S, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006, 8:1114-20.